Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) was downgraded by research analysts at from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock opened at $7.16 on Thursday. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17. The stock has a market capitalization of $150.86 million, a price-to-earnings ratio of -1.91 and a beta of 1.82. The stock has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $4.33. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 1.09.

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) last issued its earnings results on Tuesday, November 14th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.23). The business had revenue of $3.76 million during the quarter, compared to analyst estimates of $3.90 million. On average, analysts predict that Syros Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju acquired 904,977 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was purchased at an average cost of $4.42 per share, for a total transaction of $3,999,998.34. Following the purchase, the director now directly owns 1,786,427 shares of the company’s stock, valued at approximately $7,896,007.34. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.45% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC acquired a new position in shares of Syros Pharmaceuticals in the first quarter valued at about $29,000. Sawtooth Solutions LLC acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth about $29,000. Prudential Financial Inc. acquired a new stake in shares of Syros Pharmaceuticals during the second quarter worth about $32,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Syros Pharmaceuticals by 540.4% during the second quarter. BNP Paribas Arbitrage SA now owns 34,608 shares of the company’s stock worth $33,000 after purchasing an additional 29,204 shares during the period. Finally, Walleye Trading LLC purchased a new position in Syros Pharmaceuticals during the first quarter valued at approximately $36,000. 51.29% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

See Also

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with's FREE daily email newsletter.